Every material Form 8-K ASSEMBLY BIOSCIENCES, INC. has filed with the SEC since May 26, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Assembly Biosciences reported second quarter 2026 results, with collaboration revenue from Gilead rising to $13.4 million from $9.6 million and net loss falling to $3.9 million, or $0.20 per share, from $10.2 million, or $1.33 per share. The company completed $115 million in gross financing and said its cash position is projected to fund operations into 2029, which supports its pipeline programs.
Collaboration revenue was $13.4 million for the quarter ended June 30, 2026, compared with $9.6 million a year earlier, including a $5.1 million cumulative catch-up adjustment.
Net loss attributable to common stockholders was $3.9 million, or $0.20 per share, versus $10.2 million, or $1.33 per share, in the same period of 2025.
Cash, cash equivalents and marketable securities were $320.4 million at June 30, 2026, up from $226.6 million at March 31, 2026.
Completed $115 million gross financing; GS-1179 is expected to start a Phase 2 trial by year-end 2026.
At its June 4, 2026 annual meeting, Assembly Biosciences stockholders elected nine directors, approved a non-binding advisory vote on executive pay, and ratified Ernst & Young LLP as auditor for 2026. They also approved Amendment No. 3, which raises the shares reserved under the 2018 Stock Incentive Plan from 1,478,333 to 2,678,333, and an amendment that raises the shares reserved under the Employee Stock Purchase Plan from 225,000 to 515,000.
Amendment No. 3 adds 1,200,000 shares to the 2018 Stock Incentive Plan, bringing the reserve to 2,678,333 shares.
The ESPP reserve rises from 225,000 to 515,000 shares under ESPP Amendment No. 2.
Nine directors were elected, each receiving at least 11,274,020 votes for, with the ratification of Ernst & Young LLP receiving 12,382,746 votes for.
Votes against the executive pay advisory proposal totaled 5,401, against 11,293,061 votes for.
Assembly Biosciences sold 3,358,602 common shares at $26.50 each and pre-funded warrants for up to 415,000 shares, and underwriters exercised in full a 566,040-share option on May 22, 2026. The offering closed on May 26, 2026, with the company reporting net proceeds of approximately $107.4 million. The company plans to use the proceeds for clinical development of pipeline candidates and general corporate purposes, and the new shares increase the number of shares outstanding for existing shareholders.
Closed May 26, 2026, including the full exercise of a 566,040-share underwriter option on May 22, 2026.
Common shares priced at $26.50; pre-funded warrants for up to 415,000 shares priced at $26.499 each.
Gross proceeds of approximately $115.0 million; net proceeds of approximately $107.4 million after underwriting discounts and offering expenses.
Executive officers and directors agreed to a 90-day lock-up, subject to exceptions and Guggenheim Securities' consent to sell.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ASSEMBLY BIOSCIENCES, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →